Jefferies Downgrades Collegium Pharmaceutical to Hold, Raises Price Target to $37
Portfolio Pulse from Benzinga Newsdesk
Jefferies analyst Glen Santangelo downgraded Collegium Pharmaceutical (NASDAQ:COLL) from Buy to Hold while raising the price target from $30 to $37. This reflects a more cautious stance on the stock's current valuation but acknowledges potential upside.

January 04, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Collegium Pharmaceutical was downgraded by Jefferies from Buy to Hold, although the price target was increased from $30 to $37, indicating a nuanced view on the stock's future performance.
The downgrade to Hold suggests that Jefferies believes Collegium Pharmaceutical's stock may not provide significant returns in the short term, aligning with a neutral score. However, the increase in the price target implies some level of optimism about the company's prospects, which could prevent a negative impact on the stock price. The high relevance reflects the direct mention of the company, and the importance is significant due to the influence analyst ratings can have on investor sentiment. The confidence level is high as the information comes from a reputable financial analyst firm.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100